Research
Neural
GLP-1 agonists may decrease sexual desire through increased serotonergic activity at the 5-HT2C receptor.
Clinicians should consider the potential impact of GLP-1 agonists on sexual desire when prescribing these medications.
StrongSupportsmedium confidence
We established a theoretical model for how GLP-1 agonist modulation via increased serotonergic activity at the 5-HT2C receptor may result in diminished sexual desire.
Why this rating
The claim is based on a narrative review analysis of existing literature.
Source
Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don’t ‘see’ it
Sergei Gelfand et al. · Obesity Pillars · 2025
DOI 10.1016/j.obpill.2025.100233
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Neural
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →